| Not Yet Recruiting | Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SO NCT07225972 | New York Medical College | Phase 3 |
| Not Yet Recruiting | HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR NCT07210242 | Ting YANG | — |
| Recruiting | Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Al NCT07013370 | Antonello Di Paolo, M.D., Ph.D. | — |
| Recruiting | Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Pati NCT06909110 | Jessie L. Alexander | Phase 1 / Phase 2 |
| Recruiting | R-MVST Cells for Treatment of Viral Infections in Children and Young Adults NCT06926894 | Columbia University | Phase 1 |
| Recruiting | Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CM NCT06694428 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing NCT06812598 | The First Affiliated Hospital of Soochow University | N/A |
| Recruiting | Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTI NCT06341543 | University Hospital, Grenoble | N/A |
| Recruiting | Evaluation of CMV/EBV-CMI in Haploid HSCT NCT06554197 | The First Affiliated Hospital of Soochow University | — |
| Recruiting | Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients NCT06407232 | University of Wisconsin, Madison | Phase 3 |
| Recruiting | Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Ly NCT06058858 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients NCT06066957 | University of Pennsylvania | Phase 2 |
| Active Not Recruiting | Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Rec NCT07430683 | University of Guadalajara | Phase 4 |
| Enrolling By Invitation | Anti-viral T-cell Therapy by Gamma Capture NCT06027879 | Paul Szabolcs | Phase 1 / Phase 2 |
| Completed | A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants NCT06145178 | SpyBiotech Limited | Phase 1 |
| Recruiting | Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study NCT06522880 | University of Massachusetts, Worcester | — |
| Active Not Recruiting | Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation NCT05701228 | University Hospital, Bordeaux | — |
| Recruiting | Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients NCT05626530 | Tufts Medical Center | Phase 4 |
| Unknown | HCMV Breakthrough Infections During Letermovir Prophylaxis NCT06339892 | Fondazione IRCCS Policlinico San Matteo di Pavia | N/A |
| Active Not Recruiting | Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant Study NCT05532540 | Susanne Dam Nielsen, MD, DMSc | — |
| Terminated | Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute NCT05370976 | University Hospital, Lille | Phase 2 |
| Recruiting | R-MVST Cells for Treatment of Viral Infections NCT05183490 | Columbia University | Phase 1 |
| Terminated | Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic C NCT05305040 | AlloVir | Phase 2 / Phase 3 |
| Unknown | Ganciclovir Resistant Cytomegalovirus Infection in SOT Recipients. NCT05234723 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Completed | Letermovir Use in Heart Transplant Recipients NCT04904614 | Tufts Medical Center | Phase 4 |
| Withdrawn | Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection NCT02346617 | Yae-Jean Kim | Phase 1 / Phase 2 |
| Completed | Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus NCT05099965 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults NCT05089630 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Withdrawn | Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Resp NCT04936971 | Edoardo Melilli | Phase 4 |
| Completed | Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantati NCT07181330 | Ting YANG | — |
| Completed | Assessment of Post-traumatic Stress Disorder (PTSD) in Patients Monitored for Cytomegalovirus (CMV) Seroconver NCT04658810 | Hospices Civils de Lyon | — |
| Withdrawn | Inflammation and Co-Infections in D²EFT NCT04183738 | Kirby Institute | Phase 4 |
| Recruiting | Breakthrough CMV Lung Transplant -Multicentre NCT04439916 | University of Alberta | — |
| Completed | Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic NCT04693637 | AlloVir | Phase 2 / Phase 3 |
| Unknown | Study on Correlation Between Cytomegalovirus and Ocular Myasthenia Gravis NCT05091177 | XiaoYong Liu | — |
| Recruiting | ATG Individualized Dosing Model in URD-PBSCT. NCT06572462 | Chinese PLA General Hospital | Phase 2 |
| Completed | AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients NCT04690933 | University Hospital, Limoges | — |
| Completed | Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipie NCT04478474 | New York Medical College | — |
| Active Not Recruiting | Viral Specific T-Lymphocytes to Treat Adenovirus or CMV NCT04364178 | Jessie L. Alexander | Phase 1 / Phase 2 |
| Recruiting | T Cell Therapy of Opportunistic Cytomegalovirus Infection NCT02982902 | Mari Dallas | EARLY_Phase 1 |
| Completed | Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia NCT03915366 | Hospital Universitario 12 de Octubre | Phase 2 / Phase 3 |
| Terminated | Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells NCT03798301 | University of Wisconsin, Madison | Phase 1 |
| Unknown | Treatment of Low Dose IL-2 and Ganciclovir in Cytomegalovirus Infection NCT04225780 | Peking University People's Hospital | Phase 1 / Phase 2 |
| Completed | Comparison of Safety and Efficacy of de Novo Everolimus NCT04906304 | Shahid Beheshti University of Medical Sciences | N/A |
| Terminated | A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Soli NCT03950414 | University of Wisconsin, Madison | Phase 1 |
| Recruiting | QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis NCT04030676 | Centre Hospitalier Universitaire de Saint Etienne | N/A |
| Completed | Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis NCT03916497 | University Hospital, Grenoble | — |
| Completed | Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-gu NCT03699254 | Maimónides Biomedical Research Institute of Córdoba | Phase 3 |
| Completed | Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) NCT03840174 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection NCT03728426 | Amy C. Sherman, MD | Phase 2 |
| Recruiting | Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) NCT03266640 | New York Medical College | Phase 2 |
| Unknown | Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV NCT03858907 | University of Sao Paulo General Hospital | — |
| Active Not Recruiting | Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transpl NCT03475212 | Pediatric Transplantation & Cellular Therapy Consortium | Phase 1 / Phase 2 |
| Unknown | (Val)Ganciclovir TDM in Transplant Recipients NCT03698435 | University Medical Center Groningen | — |
| Unknown | Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recip NCT03576014 | SL VAXiGEN | Phase 1 |
| Unknown | Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient NCT03806764 | Melbourne Health | N/A |
| Completed | Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir NCT03631316 | Luis Eduardo Morales Buenrostro | N/A |
| Terminated | Relevance of Gastric Aspirate in HCMV Detection NCT03262194 | Centre Hospitalier Universitaire de Besancon | — |
| Unknown | Role of Endothelial Biomarkers in Patients With Coronary Artery Disease NCT03146208 | Assiut University | — |
| Unknown | Development of Potential Biomarkers for Foetal Brain Development After Congenital CMV Infection NCT03188679 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Active Not Recruiting | Non Primary HCMV Infection: Natural History and Immune Response NCT06337955 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Completed | CMV-CTL for the Treatment of CMV Infection After HSCT NCT03004261 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 |
| Completed | Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis NCT02943057 | Singapore National Eye Centre | Phase 4 |
| Completed | Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healt NCT02826798 | VBI Vaccines Inc. | Phase 1 |
| Terminated | Biochip for HCMV Detection in Breast Milk NCT02840825 | Centre Hospitalier Universitaire de Besancon | — |
| Completed | Screening for Congenital Cytomegalovirus Infection in Newborns NCT02683096 | Southern Illinois University | — |
| Completed | A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin NCT02715752 | The Center for the Biology of Chronic Disease | — |
| Completed | Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis NCT02684734 | University of British Columbia | — |
| Completed | Cell-mediated Immunity for Prevention of CMV Disease NCT02538172 | University of Lausanne Hospitals | N/A |
| Unknown | Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence NCT02671318 | Hospital do Rim e Hipertensão | Phase 4 |
| Completed | Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis NCT02439372 | Asan Medical Center | — |
| Recruiting | A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipi NCT02007356 | University Hospital, Basel, Switzerland | Phase 2 |
| Completed | Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Ther NCT02600065 | University of Erlangen-Nürnberg Medical School | — |
| Completed | The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University NCT02642822 | Jun Zhang | — |
| Completed | ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation NCT01972035 | University of Minnesota | Phase 2 |
| Unknown | Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in Pregnancy NCT02129465 | Shaare Zedek Medical Center | — |
| Unknown | The Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection NCT01081379 | Shaare Zedek Medical Center | — |
| Completed | Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients NCT02683291 | Associação Médico Espírita de Botucatu | Phase 4 |
| Completed | Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKn NCT02076971 | Fundacio Catalana de Pneumologia | — |
| Completed | Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-0 NCT01986010 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients NCT01927588 | Fundação Pró Rim | Phase 4 |
| Completed | Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Re NCT01602614 | University of Alabama at Birmingham | — |
| Completed | Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus NCT01819519 | Women and Infants Hospital of Rhode Island | N/A |
| Completed | A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Rec NCT01753167 | Genentech, Inc. | Phase 2 |
| Completed | Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Tran NCT02084446 | Ronaldo de Matos Esmeraldo, MD | Phase 4 |
| Completed | The Influence of Chronic CMV Infection on Influenza Vaccine Responses NCT02134184 | Stanford University | Phase 4 |
| Completed | Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody NCT01594437 | Theraclone Sciences, Inc. | Phase 1 |
| Completed | Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV NCT01535885 | Medical College of Wisconsin | Phase 1 |
| Completed | A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untr NCT01663740 | Hoffmann-La Roche | Phase 4 |
| Terminated | Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT NCT01274377 | Nelson Chao | Phase 1 |
| Completed | Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) NCT01070797 | Baylor College of Medicine | Phase 1 |
| Completed | Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus NCT01251744 | GlaxoSmithKline | N/A |
| Completed | Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus NCT01325636 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Completed | An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients NCT02062294 | Hoffmann-La Roche | — |
| Unknown | Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim NCT01353053 | Federal University of São Paulo | — |
| Completed | Cytomegalovirus Infection in Patients With HIV-1 Infection NCT04067869 | University Hospital, Bordeaux | Phase 3 |
| Completed | Evaluation of the Artus® CMV PCR Test NCT01034709 | QIAGEN Gaithersburg, Inc | — |
| Completed | Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipien NCT00673868 | Milton S. Hershey Medical Center | Phase 1 |
| Completed | Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomega NCT00674648 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Reci NCT00497796 | Shire | Phase 3 |
| Completed | Cytomegalovirus (CMV) Infection in Amniotic Fluid NCT00194142 | University of Pennsylvania | — |
| Terminated | Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women NCT00201448 | Virginia Commonwealth University | Phase 2 / Phase 3 |
| Completed | A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV) NCT00439803 | AlphaVax, Inc. | Phase 1 |
| Completed | Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Reci NCT00411645 | Shire | Phase 3 |
| Unknown | CMV Glycoprotein B Vaccine in Allograft Recipients NCT00299260 | University College, London | Phase 2 |
| Completed | Valganciclovir to Reduce T Cell Activation in HIV Infection NCT00264290 | University of California, San Francisco | Phase 4 |
| Completed | Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients NCT00284687 | Hadassah Medical Organization | Phase 3 |
| Completed | Cytomegalovirus Cell-Mediated Immunity NCT00815165 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females NCT00133497 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | CMV Infection in Adolescent Males NCT00302029 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation NCT00372229 | Hoffmann-La Roche | Phase 3 |
| Completed | IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Al NCT00294515 | Hoffmann-La Roche | Phase 3 |
| Terminated | Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy NCT00264368 | University of Oslo School of Pharmacy | Phase 4 |
| Unknown | Genotyping of Cytomegalovirus From Patients in Israel NCT00228202 | Sheba Medical Center | — |
| Completed | A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cys NCT00377741 | Hoffmann-La Roche | Phase 1 |
| Completed | Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation NCT00170170 | Mayo Clinic | — |
| Terminated | Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomega NCT00241345 | Washington University School of Medicine | Phase 3 |
| Completed | A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients NCT00090766 | Hoffmann-La Roche | Phase 2 / Phase 3 |
| Completed | Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors NCT00353977 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovi NCT00431353 | Hoffmann-La Roche | Phase 4 |
| Completed | Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant NCT00078533 | Baylor College of Medicine | Phase 1 |
| Terminated | MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cyt NCT00237653 | University Hospital, Grenoble | Phase 3 |
| Completed | Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplan NCT00227370 | Duke University | Phase 3 |
| Completed | Valganciclovir in Congenital CMV Infants NCT00031434 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Immune Response to Cytomegalovirus NCT00034437 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Neonatal CMV-Ganciclovir Follow-up Study NCT00031421 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV NCT00566072 | University Hospital, Ghent | N/A |
| Completed | Transfusion Infections Pediatric Prospective Study (TRIPPS) NCT00029406 | Naomi Luban | — |
| Completed | Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV NCT00006145 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Recombinant CMV gB Vaccine in Postpartum Women NCT00125502 | Robert Pass, MD | Phase 2 |
| Completed | Cytomegalovirus Spread and Reactivation in Blood Cells NCT00006314 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections NCT00001890 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Infection and Cardiovascular Disease NCT00005547 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Inflammation, Infection, and Future Cardiovascular Risk NCT00005496 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients NCT00001082 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction NCT00001531 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic NCT00004642 | National Center for Research Resources (NCRR) | Phase 1 / Phase 2 |
| Completed | Viral Activation Transfusion Study (VATS) NCT00000593 | National Heart, Lung, and Blood Institute (NHLBI) | N/A |
| Completed | Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection NCT00004278 | National Center for Research Resources (NCRR) | Phase 3 |
| Completed | Prospective Study of HIV Infection in Hemophiliacs NCT00005309 | Bloodworks | — |
| Completed | Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2) NCT00005274 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Transfusion-Transmitted Cytomegalovirus Prevention in Neonates NCT00000584 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
| Completed | The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS NCT00000981 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised NCT00002025 | Hoffmann-La Roche | N/A |
| Available | TETRAVI Expanded Access Program NCT07104591 | Baylor College of Medicine | — |
| Completed | A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Inf NCT00001038 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients NCT00001089 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) T NCT00001100 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zi NCT00002096 | Hoffmann-La Roche | Phase 1 |
| Completed | A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegal NCT00000805 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Unknown | Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR NCT00004573 | National Center for Research Resources (NCRR) | N/A |
| Completed | A Study of Lobucavir in Patients With AIDS NCT00002352 | Bristol-Myers Squibb | N/A |
| Completed | A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection NCT00000995 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection NCT00005572 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Dise NCT00002095 | Hoffmann-La Roche | N/A |
| Completed | The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of NCT00002373 | Glaxo Wellcome | Phase 1 |
| Completed | A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti- NCT00002268 | Sandoz | Phase 1 |
| Completed | Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Lev NCT00002146 | Astra USA | Phase 4 |
| Withdrawn | A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease NCT00000881 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Gan NCT00002251 | Hoffmann-La Roche | N/A |
| Completed | Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections NCT00002024 | Hoffmann-La Roche | N/A |